Letros 2,5 mg Pharmacom Labs

Letros 2,5 mg Pharmacom Labs: instructions for use

Conventionally, all anabolic steroids can be divided into 2 main groups: aromatising and non-aromatising. Aromatisation is the process by which a male sex hormone is converted into a female hormone (oestrogen). As a result, oestrogen accumulates in the male body and causes various side effects.

There is a way to prevent the aromatisation process: you should take Letros 2,5 mg Pharmacom Labs . The composition contains Letros 2,5 mg Pharmacom Labs, which blocks aromatase and prevents it from converting hormones. As a result, no side effects develop, male sex hormones remain at the required level.

Main positive effects of Letros 2,5 mg Pharmacom Labs

Excess oestrogen leads to undesirable consequences for men: gynaecomastia, bloating, high blood pressure. Taking aromatase inhibitors such as Letros helps to avoid these problems. In addition, the tablets help to eliminate the first manifestations of side effects in the course of steroids.

Other positive effects of the drug:

• increases the level of anabolic hormones in the blood;
• expels excess water, thereby improving relief;
• supports the production of natural testosterone.

Consequently, after a course of steroids, it will be easier to restore the level of endogenous testosterone, which inevitably falls when taking anabolic steroids.

Before taking Letros Pharmacom Labs 2.5mg you should know if the selected anabolic steroid is aromatized. If it is not converted to oestrogen, the drug is not needed. If it is testosterone or its derivatives, aromatase inhibitors are a must.

Possible side effects

Normally, oestrogen is also present in a man’s body and performs important positive functions. The main thing is that the ratio of oestrogen and testosterone is observed. If it is violated in either direction, problems begin. In the event that aromatase inhibitors reduce the levels of oestrogen in the blood too much, the following problems can occur:

• slow muscle growth;
• joint pain
• loss of bone strength;
• increased cholesterol levels;
• weak libido;
• lack of motivation, depression.

Occur rarely and only in cases where large doses are used for a long time. Compared to anti-oestrogens (they block oestrogen receptors, not the aromatase enzyme), aromatase inhibitors are more easily tolerated.

Dosage and dosing rules

Letros 2,5 mg Pharmacom Labs can be taken for several purposes. To prevent side effects (prophylaxis), it is recommended to take 0.5 mg of the drug every other day. Since the tablets are available in a dosage of 2.5 mg, for prevention, the tablet should be divided into 5 parts.

Other use: when symptoms of gynaecomastia appear. These include reddening of the breasts, itching and nipple tenderness. In addition, the breast begins to enlarge and pains appear. In this case, take 2.5 mg per day. The dosage is maintained until all symptoms of gynaecomastia disappear. Only then can you switch to a prophylactic dosage.

Ideally, an athlete should have an oestrogen test and monitor the oestrogen level. This will help him to understand when the course can be completed. For the use of aromatase inhibitors, it is best to consult your doctor to find out if you have any contraindications. All experienced athletes taking anabolic steroids prone to aromatization cannot do without drugs like Letros.

List of references

1. Ellis MJ, Coop A, Singh B, Mauriac L, Llombart-Cussac A, Janicke F, Miller WR, Evans DB, Dugan M, Brady C, Quebe-Fehling E, Borgs M. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. Journal of Clinical Oncology. 2001;19(18):3808-3816.
2. Buzdar AU, Robertson JF, Eiermann W, Nabholtz JM. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer. 2002;95(9):2006-2016.
3. Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A; Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. The New England Journal of Medicine. 2005;353(26):2747-2757.
4. Ellis MJ, Suman VJ, Hoog J, Goncalves R, Sanati S, Creighton CJ, DeSchryver K, Crouch E, Brink A, Watson M, Luo J, Tao Y, Barnes M, Dowsett M, Budd GT, Winer EP, Silverman P, Esserman L, Carey L, Ma CX. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). Journal of Clinical Oncology. 2017;35(10):1061-1069.
5. Sukumvanich P, Case LD, Van Zee K, Singletary SE, Paskett ED, Petrek JA, Naftalis E, Naughton MJ, Paggiarino DA, Inc N, Newman LA. Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment: a prospective study. Cancer. 2010;116(13):3102-3111.